Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8407 | TAGLN2 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 8.86e-16 | 9.39e-01 | -0.1972 |
8407 | TAGLN2 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 1.70e-08 | 7.78e-01 | -0.2126 |
8407 | TAGLN2 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 1.52e-12 | 9.59e-01 | -0.2027 |
8407 | TAGLN2 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 9.40e-04 | 4.58e-01 | -0.1433 |
8407 | TAGLN2 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 6.31e-19 | 1.05e+00 | -0.1833 |
8407 | TAGLN2 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.14e-06 | 7.18e-01 | -0.23 |
8407 | TAGLN2 | 047563_1562-all-cells | Human | Prostate | BPH | 8.70e-27 | -2.70e-01 | 0.0791 |
8407 | TAGLN2 | 048752_1579-all-cells | Human | Prostate | BPH | 5.23e-07 | -3.38e-01 | 0.1008 |
8407 | TAGLN2 | 052097_1595-all-cells | Human | Prostate | BPH | 2.42e-04 | -3.05e-01 | 0.0972 |
8407 | TAGLN2 | 052099_1652-all-cells | Human | Prostate | BPH | 1.11e-09 | -4.22e-01 | 0.1038 |
8407 | TAGLN2 | Dong_P1 | Human | Prostate | Tumor | 2.13e-17 | 3.48e-01 | 0.035 |
8407 | TAGLN2 | Dong_P3 | Human | Prostate | Tumor | 8.50e-06 | 3.75e-02 | 0.0278 |
8407 | TAGLN2 | Dong_P5 | Human | Prostate | Tumor | 7.36e-24 | 5.17e-01 | 0.053 |
8407 | TAGLN2 | P7 | Human | Prostate | Tumor | 2.72e-03 | 1.60e-01 | -0.1025 |
8407 | TAGLN2 | P10 | Human | Prostate | Tumor | 2.40e-08 | 2.50e-01 | -0.0902 |
8407 | TAGLN2 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.64e-03 | -7.16e-01 | 0.1557 |
8407 | TAGLN2 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.43e-03 | -5.63e-01 | 0.159 |
8407 | TAGLN2 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 9.35e-03 | -7.01e-01 | 0.1531 |
8407 | TAGLN2 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.94e-09 | -5.59e-01 | 0.1608 |
8407 | TAGLN2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 1.40e-02 | -4.81e-01 | 0.1604 |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TAGLN2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TAGLN2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TAGLN2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TAGLN2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TAGLN2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAGLN2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TAGLN2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAGLN2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TAGLN2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TAGLN2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TAGLN2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAGLN2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAGLN2 | SNV | Missense_Mutation | | c.460N>C | p.Gly154Arg | p.G154R | P37802 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TAGLN2 | insertion | Frame_Shift_Ins | novel | c.428_429insATGGCTCTCGAGGGCAGAGCTGGCACCAGCCCTTGAGCCAACAGCAA | p.Met143IlefsTer24 | p.M143Ifs*24 | P37802 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
TAGLN2 | SNV | Missense_Mutation | rs369414441 | c.607C>T | p.Arg203Cys | p.R203C | P37802 | protein_coding | tolerated(0.14) | benign(0.033) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TAGLN2 | SNV | Missense_Mutation | novel | c.262N>C | p.Asn88His | p.N88H | P37802 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
TAGLN2 | SNV | Missense_Mutation | | c.300G>T | p.Lys100Asn | p.K100N | P37802 | protein_coding | tolerated(0.11) | benign(0.205) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TAGLN2 | SNV | Missense_Mutation | novel | c.472G>A | p.Val158Ile | p.V158I | P37802 | protein_coding | deleterious(0.04) | benign(0.015) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
TAGLN2 | SNV | Missense_Mutation | novel | c.239N>A | p.Gly80Asp | p.G80D | P37802 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAGLN2 | SNV | Missense_Mutation | novel | c.522N>T | p.Lys174Asn | p.K174N | P37802 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAGLN2 | SNV | Missense_Mutation | novel | c.336N>T | p.Glu112Asp | p.E112D | P37802 | protein_coding | deleterious(0.01) | benign(0.344) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
TAGLN2 | SNV | Missense_Mutation | rs373828343 | c.41C>T | p.Pro14Leu | p.P14L | P37802 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.988) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |